1. Home
  2. AMTB vs MNKD Comparison

AMTB vs MNKD Comparison

Compare AMTB & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amerant Bancorp Inc.

AMTB

Amerant Bancorp Inc.

HOLD

Current Price

$22.51

Market Cap

922.1M

Sector

Finance

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$3.33

Market Cap

877.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMTB
MNKD
Founded
1979
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
922.1M
877.0M
IPO Year
2018
2004

Fundamental Metrics

Financial Performance
Metric
AMTB
MNKD
Price
$22.51
$3.33
Analyst Decision
Buy
Buy
Analyst Count
3
8
Target Price
$23.67
$8.69
AVG Volume (30 Days)
201.2K
6.0M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
1.57%
N/A
EPS Growth
386.36
N/A
EPS
0.44
N/A
Revenue
N/A
$348,966,000.00
Revenue This Year
$8.29
$35.81
Revenue Next Year
$7.67
$11.89
P/E Ratio
$50.80
N/A
Revenue Growth
N/A
22.23
52 Week Low
$15.62
$2.23
52 Week High
$24.38
$6.51

Technical Indicators

Market Signals
Indicator
AMTB
MNKD
Relative Strength Index (RSI) 44.58 59.70
Support Level $21.98 $2.45
Resistance Level $22.75 $6.08
Average True Range (ATR) 0.57 0.26
MACD -0.09 0.01
Stochastic Oscillator 49.13 34.25

Price Performance

Historical Comparison
AMTB
MNKD

About AMTB Amerant Bancorp Inc.

Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: